INHIBITION OF THE PLATELET-AGGREGATING ACTIVITY OF 2 HUMAN ADENOCARCINOMAS OF THE COLON AND AN ANAPLASTIC MURINE TUMOR WITH A SPECIFIC THROMBIN INHIBITOR, DANSYLARGININE N-(3-ETHYL-1,5-PENTANEDIYL)AMIDE
- 1 January 1981
- journal article
- research article
- Vol. 41 (11) , 4535-4539
Abstract
Platelets are required for certain experimental metastases. Several lines of animal tumor cells aggregate platelets in vitro and in vivo. Previous studies with one of these lines, an SV40-transformed 3T3 mouse fibroblast (SV3T3) have revealed that the platelet-aggregating material is an extractable membrane-associated sialolipoprotein which requires divalent cation, complement and a heat-stable plasma component for activity. Little information is available on the interaction of human tumors with platelets. The ability of 2 human adenocarcinomas of the colon (LoVo and HCT-8) and an anaplastic mouse tumor (Hut-20) to aggregate platelets by a different mechanism, the generation of thrombin was studied. These spontaneous cell lines aggregate human or rabbit platelet-rich plasma after a 1- to 2-min lag period. This is often followed by a visible clot. Unlike SV3T3 cells, aggregation by LoVo, HCT-8 and Hut-20 cells is not inhibited by neuraminidase, trypsin or cobra venom factor. These 3 cell lines markedly shorten the recalcification time of citrated plasma; SV3T3 cells do not. Phospholipase A2 treatment inhibits the shortening of the recalcification time for the 3 tumors; this parallels its inhibitory effect on platelet aggregation. LoVo, HCT-8 and Hut-20 cells generate thrombin via the tissue factor coagulation pathway (using coagulation factor-deficient substrates). Dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide, a highly specific, potent antithrombin antagonist, inhibits LoVo-, HCT-8- and Hut-20-induced platelet aggregation at 4-15 .mu.M; its effect on SV3T3 cells is negligible. If platelets are required for certain human tumor metastases, dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide or other antithrombin agents, may prove to be valuable therapeutic agents.This publication has 18 references indexed in Scilit:
- Prostaglandin D2 formation by malignant melanoma cells correlates inversely with cellular metastatic potential.Proceedings of the National Academy of Sciences, 1979
- Interactions of a fluorescent active-site-directed inhibitor of thrombin: dansylarginine N-(3-ethyl-1,5-pentanediyl)amideBiochemistry, 1979
- EXTRACTION AND CHARACTERIZATION OF A PLATELET-AGGREGATING MATERIAL FROM SV40-TRANSFORMED MOUSE 3T3 FIBROBLASTS1979
- Properties of the factor Xa binding site on human platelets.Journal of Biological Chemistry, 1978
- AGGREGATION OF PLATELETS AND CELL-MEMBRANE VESICULATION BY RAT CELLS TRANSFORMED INVITRO BY ROUS-SARCOMA VIRUS1978
- COMPARISON OF PROCOAGULANT ACTIVITY IN TISSUE-CULTURE MEDIUM FROM NORMAL AND TRANSFORMED FIBROBLASTS1978
- PLATELET AGGREGATING MATERIAL IN MOUSE TUMOR-CELLS - REMOVAL AND REGENERATION1977
- Effects of trypsin on the platelet-aggregating activity of mouse tumor cellsThrombosis Research, 1977
- The Effect of Antithrombin III on the Activity of the Coagulation Factors VII, IX and XThrombosis and Haemostasis, 1976
- Thrombogenic activity of mouse and human tumors: effects on platelets, coagulation, and fibrinolysis, and possible significance for metastasesZeitschrift für Krebsforschung und Klinische Onkologie, 1976